Ontology highlight
ABSTRACT: Background
Statins reduce plasma low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) levels. Rosuvastatin 10 mg daily appears to be more potent in reducing LDL-C than simvastatin 40 mg, but the relative effect of these two statin doses on hsCRP is unknown.Methods
Chinese hyperlipidaemic patients with high cardiovascular risk or familial hypercholesterolaemia (FH) were treated with rosuvastatin 10 mg and simvastatin 40 mg daily in an open-label crossover study. Lipid profiles were measured off treatment and after at least 4 weeks treatment with each of the two statins and hsCRP levels were measured on treatment with both statins.Results
Both treatments were well tolerated in 247 patients (age 55.7 ± 11.1 years; 100 male; 140 wi
SUBMITTER: Ding C
PROVIDER: S-EPMC4568069 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature